Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Drug Metab Dispos ; 38(3): 484-90, 2010 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-20007297

RESUMO

The extrahepatic UDP-glucuronosyltransferase 1A10 (UGT1A10) is a phase II metabolizing enzyme that is active against a number of potent carcinogens. In the present study, UGT1A10 was examined for activity against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), the major procarcinogenic metabolite of the potent tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, and the promoter region of UGT1A10 was examined for variants that could lead to altered UGT1A10 expression. UGT1A10-overexpressing cell homogenates exhibited high O-glucuronidation activity against NNAL (K(M) = 5.95 mM). A 2000-base pair (bp) product corresponding to the UGT1A10 proximal promoter region was polymerase chain reaction (PCR)-amplified using genomic DNA from 97 white subjects, and 42 of these were sequenced. In addition to a previously reported C/G single-nucleotide polymorphism at -1271 bp (rs2741032), a novel 1664-bp deletion located between nucleotides -190 to -1856 relative to the UGT1A10 translation start site was identified. Using real-time multiplex PCR, this deletion exhibited a prevalence of 0.022 in whites (n = 156) and 0.056 in blacks (n = 133). To determine whether either polymorphism altered gene expression, in vitro assays were performed using luciferase constructs containing up to 2000 bp of the proximal UGT1A10 promoter. Constructs containing the 1664-bp deletion exhibited a significant (p = 0.009) 3-fold increase in luciferase activity compared with constructs containing the wild-type UGT1A10 promoter. No effect on luciferase activity was observed for the UGT1A10(-1271G) promoter variant. These data are consistent with previous studies that indicate the presence of a transcriptional repressor element within the newly identified deletion and that this deletion polymorphism may contribute to altered UGT1A10 expression and altered carcinogen detoxification between individuals.


Assuntos
Carcinógenos/metabolismo , Carcinoma Hepatocelular/genética , Glucuronosiltransferase/genética , Glucuronosiltransferase/metabolismo , Nitrosaminas/metabolismo , Polimorfismo Genético , Regiões Promotoras Genéticas , Piridinas/metabolismo , Células CACO-2 , Carcinoma Hepatocelular/enzimologia , Carcinoma Hepatocelular/cirurgia , Regulação Neoplásica da Expressão Gênica/genética , Frequência do Gene , Genes Reporter , Estudos de Associação Genética , Predisposição Genética para Doença/etnologia , Variação Estrutural do Genoma , Glucuronosiltransferase/biossíntese , Humanos , Isoenzimas/biossíntese , Isoenzimas/genética , Isoenzimas/metabolismo , Neoplasias Hepáticas/enzimologia , Neoplasias Hepáticas/genética , Neoplasias Hepáticas/cirurgia , Desintoxicação Metabólica Fase II/genética , Antígenos de Histocompatibilidade Menor , Polimorfismo de Nucleotídeo Único , Deleção de Sequência/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA